Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Dow
Baxter
AstraZeneca
Moodys
Merck

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR IBRUTINIB

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Ibrutinib

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01217749 Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL Completed Ohio State University Phase 1/Phase 2 2010-12-01 The purpose of this study is to determine the efficacy and safety of a fixed-dose, daily regimen of orally administered PCI-32765 combined with ofatumumab in subjects with relapsed/refractory CLL/SLL and related diseases
NCT01217749 Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL Completed Pharmacyclics LLC. Phase 1/Phase 2 2010-12-01 The purpose of this study is to determine the efficacy and safety of a fixed-dose, daily regimen of orally administered PCI-32765 combined with ofatumumab in subjects with relapsed/refractory CLL/SLL and related diseases
NCT01236391 Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL) Completed Janssen Pharmaceuticals Phase 2 2011-02-01 The primary objective of this study was to evaluate the efficacy of ibrutinib in participants with relapsed or refractory MCL. The secondary objective was to evaluate the safety of a fixed daily dosing regimen (560 mg daily) of PCI-32765 in this population.
NCT01236391 Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL) Completed Pharmacyclics LLC. Phase 2 2011-02-01 The primary objective of this study was to evaluate the efficacy of ibrutinib in participants with relapsed or refractory MCL. The secondary objective was to evaluate the safety of a fixed daily dosing regimen (560 mg daily) of PCI-32765 in this population.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Ibrutinib

Condition Name

Condition Name for Ibrutinib
Intervention Trials
Chronic Lymphocytic Leukemia 52
Mantle Cell Lymphoma 27
Small Lymphocytic Lymphoma 20
Lymphoma 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Ibrutinib
Intervention Trials
Lymphoma 136
Leukemia, Lymphoid 105
Leukemia, Lymphocytic, Chronic, B-Cell 103
Leukemia 98
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Ibrutinib

Trials by Country

Trials by Country for Ibrutinib
Location Trials
United States 865
France 51
Canada 49
Spain 45
United Kingdom 42
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Ibrutinib
Location Trials
California 72
Texas 62
New York 57
Ohio 51
New Jersey 39
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Ibrutinib

Clinical Trial Phase

Clinical Trial Phase for Ibrutinib
Clinical Trial Phase Trials
Phase 4 4
Phase 3 33
Phase 2/Phase 3 2
[disabled in preview] 115
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Ibrutinib
Clinical Trial Phase Trials
Recruiting 142
Not yet recruiting 68
Active, not recruiting 38
[disabled in preview] 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Ibrutinib

Sponsor Name

Sponsor Name for Ibrutinib
Sponsor Trials
Pharmacyclics LLC. 70
National Cancer Institute (NCI) 55
Janssen Research & Development, LLC 37
[disabled in preview] 23
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Ibrutinib
Sponsor Trials
Industry 225
Other 180
NIH 58
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Medtronic
McKesson
Boehringer Ingelheim
McKinsey
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.